Sunday, October 11, 2026

NASDAQ 100 Over 5% Up In The Last 21 Sessions

NASDAQ 100 Over 5% Up In The Last 21 Sessions

(VIANEWS) - NASDAQ 100 (NDX) has been up by 5.32% for the last 21 sessions. At 22:08 EST on Sunday, 23 June, NASDAQ 100 (NDX) is $19,700.43.

Volume

Today's last reported volume for NASDAQ 100 is 2607219000, 3.65% above its average volume of 2515331403.02.

About NASDAQ 100's yearly highs and lows, it's 40.13% up from its 52-week low and 1.4% down from its 52-week high.

Volatility

NASDAQ 100's last week, last month's, and last quarter's current intraday variation average was a negative 0.34%, a positive 0.30%, and a positive 0.73%, respectively.

NASDAQ 100's highest amplitude of average volatility was 0.36% (last week), 0.64% (last month), and 0.73% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NASDAQ 100's is considered to be overbought (>=80).

More news about NASDAQ 100 (NDX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,369 source documents archived
Query this data → isubstrate.com